CDK2 and cancer: CDK2, CDK7, and CDK9 are also popular CDK targets in cancers, including CDK2-specific inhibitors (i.e., PF-07104091, INX-315, and INCB123667), CDK7-specific inhibitors (i.e., samuraciclib, SY-5609, Q901, and XL102), and CDK9-specific inhibitors (i.e., enitociclib, AZD4573, KB-0742, and GFH009), as well as more promiscuous CDK inhibitors (e.g., dinaciclib, fadraciclib, roniciclib, voruciclib, and riviciclib hydrochloride).